Co-Authors
This is a "connection" page, showing publications co-authored by Zhengyin Liu and Xiaowei Yan.
Connection Strength
0.681
-
Dynamic landscape mapping of humoral immunity to SARS-CoV-2 identifies non-structural protein antibodies associated with the survival of critical COVID-19 patients. Signal Transduct Target Ther. 2021 08 17; 6(1):304.
Score: 0.060
-
ECCO2R in 12 COVID-19 ARDS Patients With Extremely Low Compliance and Refractory Hypercapnia. Front Med (Lausanne). 2021; 8:654658.
Score: 0.060
-
Association between tachyarrhythmia and mortality in a cohort of critically ill patients with coronavirus disease 2019 (COVID-19). Ann Transl Med. 2021 May; 9(10):883.
Score: 0.059
-
Clinical characteristics and survival analysis in critical and non-critical patients with COVID-19 in Wuhan, China: a single-center retrospective case control study. Sci Rep. 2020 10 16; 10(1):17524.
Score: 0.057
-
Myocardial Injury on Admission as a Risk in Critically Ill COVID-19 Patients: A Retrospective in-ICU Study. J Cardiothorac Vasc Anesth. 2021 Mar; 35(3):846-853.
Score: 0.057
-
Antiphospholipid Antibodies in Critically Ill Patients With COVID-19. Arthritis Rheumatol. 2020 12; 72(12):1998-2004.
Score: 0.057
-
Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients. J Thromb Thrombolysis. 2020 Oct; 50(3):580-586.
Score: 0.057
-
Clinicopathological Features and Outcomes of Acute Kidney Injury in Critically Ill COVID-19 with Prolonged Disease Course: A Retrospective Cohort. J Am Soc Nephrol. 2020 09; 31(9):2205-2221.
Score: 0.056
-
Neurological Manifestations in Critically Ill Patients With COVID-19: A Retrospective Study. Front Neurol. 2020; 11:806.
Score: 0.056
-
Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med. 2020 04 23; 382(17):e38.
Score: 0.055
-
Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19. Clin Immunol. 2020 05; 214:108408.
Score: 0.055
-
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin Immunol. 2020 05; 214:108393.
Score: 0.055